NCT05898542 Nature-based Therapies in Stroke Rehabilitation
| NCT ID | NCT05898542 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Joint Authority for Päijät-Häme Social and Health Care |
| Condition | Rehabilitation |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-05-31 |
| Primary Completion | 2026-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-05-31 with a primary completion date of 2026-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke rehabilitation patients are subjected to additional nature-based therapies during a rehabilitation ward period.
Eligibility Criteria
Inclusion Criteria: * Acute/Subacute stroke * Rehabilitation ward patient Exclusion Criteria: * Incapable of independent decision making * Traumatic bleeding in brain tissue * Severe aphasia * Severe, malign ongoing disease
Contact & Investigator
Hanna Haveri, MD PhD
STUDY DIRECTOR
Päijät-Hämeen Hyvinvointialue
Frequently Asked Questions
Who can join the NCT05898542 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rehabilitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05898542 currently recruiting?
Yes, NCT05898542 is actively recruiting participants. Contact the research team at hanna.haveri@paijatha.fi for enrollment information.
Where is the NCT05898542 trial being conducted?
This trial is being conducted at Lahti, Finland.
Who is sponsoring the NCT05898542 clinical trial?
NCT05898542 is sponsored by Joint Authority for Päijät-Häme Social and Health Care. The principal investigator is Hanna Haveri, MD PhD at Päijät-Hämeen Hyvinvointialue. The trial plans to enroll 60 participants.